In the 2025 capability verification activity of China National Institute for Food and Drug Control, Shandong Xinbo successfully completed 7 testing tasks and submitted results based on its solid technical accumulation, focusing on the four core testing directions of genetic toxicity, reproductive toxicity, clinical testing, and pathological technology. After authoritative evaluation, all 7 tests passed with "satisfactory" results!

This achievement is not only an official recognition of the company's testing capabilities, but also confirms that Shandong Xinbo has industry-leading technical standards and data credibility in the field of high demand and high difficulty professional testing, laying a solid foundation for providing reliable testing services to customers.

Jinan Laboratory

Linyi Laboratory

Strength support: the core competitiveness behind achievements
>>>>Professional team escorts
The core technical personnel have over 10 years of professional experience, covering fields such as toxicology, clinical medicine, and pathology, and many hold industry authoritative certification certificates;
>>>>Empowering cutting-edge equipment
Equipped with internationally advanced equipment such as fully automatic chromosome analysis system and chemiluminescence immunoassay analyzer, the detection accuracy reaches the international advanced level;
>>>>Strict quality control guarantee
Establish a full process SOP for "sample traceability experimental operation data review", where each test result undergoes triple review to ensure "zero error and reproducibility".

Shandong Xinbo was established in April 2010, with Jinan Laboratory and Linyi Laboratory. It is a national high-tech enterprise, Shandong Enterprise Technology Center, Shandong Gazelle Enterprise, and a research service-oriented enterprise that integrates pharmacological research, toxicology research, drug analysis and testing services, animal pathology testing, and medical device evaluation services. We have completed preclinical safety evaluations for over 400 innovative drugs, including chemical drugs, traditional Chinese medicine and natural medicines, biological products, preventive and therapeutic vaccines, monoclonal antibodies, cell therapy products, medical devices, and other varieties.